Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | ERN1 | O75460 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364404 | 0.83 | LMNA (0.58) | TDP1LMNAMEN1KMT2ATHRB | |
| SCHEMBL652955 | 0.83 | LMNA (0.58) | TDP1LMNAMEN1KMT2ATHRB | |
| SCHEMBL986911 | 0.78 | TDP1 (0.52) | TDP1LMNAMEN1KMT2ATHRB | |
| SCHEMBL547777 | 0.78 | TDP1 (0.52) | TDP1LMNAMEN1KMT2ATHRB | |
| SCHEMBL30402244 | 0.78 | TDP1 (0.52) | TDP1LMNAMEN1KMT2ATHRB | |
| SCHEMBL3134002 | 0.77 | TDP1 (0.59) | TDP1LMNAMEN1KMT2ATHRB | |
| SCHEMBL23527770 | 0.77 | HASPIN (0.53) | TDP1ERN1ALDH1A1CYP2A6GAA | |
| SCHEMBL22652708 | 0.77 | ERN1 (0.52) | TDP1ERN1CYP2A6 | |
| SCHEMBL10041729 | 0.77 | TDP1 (0.50) | TDP1ERN1CYP2A6 | |
| SCHEMBL3412523 | 0.75 | CASP6 (0.57) | TDP1LMNAMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| EP-3625228-B1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-07 | — | — | EP | disclosed |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | disclosed |
| EP-3625228-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| CN-110612299-A | Pyrimidine derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2019-12-24 | — | — | CN | disclosed |
| WO-2018210988-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| US-RE39590-E1 | Substituted benzene compounds, process for their preparation, and herbicidal and defoliant compositions containing them | ISK AMERICAS INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
| CN-1680274-A | Substituted benzene compounds, process for their preparation, and herbicidal and defoliant compositions containing them | ISK AMERICAS INC (US) | 2005-10-12 | — | — | CN | disclosed |
| CN-1673219-A | Substituted benzene compounds, process for their preparation, and herbicidal and defoliant compositions containing them | ISK AMERICAS INC (US) | 2005-09-28 | — | — | CN | disclosed |
| US-20030171422-A1 | New nitromethyl ketones, process for preparing them and compositions containing them | MERCK PATENT GMBH (DE) | 2003-09-11 | — | — | US | disclosed |
| US-6559185-B2 | Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use | MERCK PATENT GMBH (DE) | 2003-05-06 | — | — | US | disclosed |
| US-20030069312-A1 | Antidiabetic agents | LARDY CLAUDE (FR) | 2003-04-10 | — | — | US | disclosed |
| US-6545161-B2 | Potato and corn crops | ISK AMERICAS INCORPORATED | 2003-04-08 | — | — | US | disclosed |
| US-6043281-A | ALDOSE REDUCTASE INHIBITORS; TREATMENT OR PREVENTION OF COMPLICATIONS OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-03-28 | — | — | US | disclosed |
| EP-0983226-A1 | NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM | MERCK PATENT GmbH (DE) | 2000-03-08 | — | — | EP | disclosed |
| US-5932765-A | REDUCTASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT (DE) | 1999-08-03 | — | — | US | disclosed |
| WO-1998052906-A1 | NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM | MERCK PATENT GMBH (DE) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069312-A1 | Antidiabetic agents | SLC5A1, SLC5A2, GPR119 | TDP1 2860/4885LMNA 1633/4885MEN1 3488/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | TDP1 2322/4885LMNA 4601/4885MEN1 4485/4885 |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | TDP1 2322/4885LMNA 4601/4885MEN1 4485/4885 |
| US-20030171422-A1 | New nitromethyl ketones, process for preparing them and compositions containing them | AKR1B1, AKR1A1, AKR1C1 | TDP1 2738/4885LMNA 578/4885MEN1 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.